Thanks for clarifying this. Someone with a medical background or understanding of clinical evidence needed to clarify the relevance of an anecdotal case to practice guidelines (and thus adoption of a new therapy).
I noticed on the NAN threads that investors (perhaps laypeople) are excited about endoscopy-related complications, which is entirely separate from ultrasound technologies!
SRX Price at posting:
$33.25 Sentiment: None Disclosure: Not Held
